Pharmacist administration of long-acting injectable medications for substance use disorders: A scoping review [0.03%]
物质使用障碍长效注射药物的药剂师管理：系统性回顾
Pamela Hernandez Bustamante,Amanda Charles,Marissa Snider et al.
Pamela Hernandez Bustamante et al.
Introduction: Using long-acting injectable (LAI) medications increases treatment adherence and promotes positive outcomes for patients with substance use disorders (SUD). Despite documented benefits that LAI medications can have over their ...
Clinical pearls for the management of duloxetine patients with medical comorbidities [0.03%]
伴有合并症的度洛西汀患者的管理临床经验珠玑
Megan O&#x;Connell,Amy VandenBerg
Megan O&#x;Connell
The effective use of duloxetine can be complicated by acute kidney injury, acute and/or chronic hepatic dysfunction, dysphagia, enteral nutrition, and common pharmacokinetic interactions. This article aimed to review the pharmacological pro...
Clinical experience and treatment considerations with vesicular monoamine transport 2 inhibitors [0.03%]
临床使用以及对vmat-2抑制剂的治疗思考
Kayla Johnson
Kayla Johnson
Vesicular monoamine transporter 2 inhibitors (VMAT2i) are currently Food and Drug Administration-approved for the treatment of Huntington disease chorea and tardive dyskinesia. Additionally, they are often used for other hyperkinetic moveme...
Exacerbation of neuropsychiatric symptoms in an adult male with influenza A virus treated with oseltamivir [0.03%]
奥司他韦治疗成人甲型流感所致神经精神症状加重
Masa Scott,Emily Faltin,Kathleen Londick
Masa Scott
Oseltamivir (Tamiflu) package labeling has a warning for neuropsychiatric adverse events (NPAE), most commonly in children and adolescents, especially males. There are several case reports of NPAE in adults treated with oseltamivir, but few...
Suicide risk identification and mitigation in patients with chronic pain prescribed opioid medication [0.03%]
慢性疼痛患者使用阿片类药物的风险识别与缓解
Dana L Chiulli
Dana L Chiulli
Managing suicidality in persons with chronic pain is a challenging clinical scenario with no treatment guidelines to inform clinical decision-making related to suicide risk mitigation. Applying appropriate risk mitigation strategies, such a...
Appropriate use of single-dose injectable aripiprazole lauroxil in the treatment of schizophrenia [0.03%]
阿立哌唑棕榈酸酯单次注射治疗精神分裂症的合理使用
Rachael C Davis,Jianing Xu,Daniel B Hall et al.
Rachael C Davis et al.
Introduction: Single-dose injectable aripiprazole lauroxil (SDIAL) is used with long-acting injectable (LAI) aripiprazole lauroxil in the treatment of schizophrenia. SDIAL can be used to either initiate treatment or suppl...
Involuntary medication treatment of schizophrenia in the inpatient setting [0.03%]
住院患者的精神分裂症非自愿药物治疗
Courtney A Iuppa
Courtney A Iuppa
Two Supreme Court cases in the United States describe the use of involuntary medication in individuals with mental illnesses. In addition to these legal requirements, clinicians must also incorporate ethics into treating these individuals, ...
Caitlin Burton,S Andrea Laguado
Caitlin Burton
Risperidone is a second-generation antipsychotic with common adverse effects, such as extrapyramidal symptoms, weight gain, hyperprolactinemia, and sedation. Angioedema, although generally considered to be uncommon, has previously been docu...
Delayed allergic reaction from bupropion in a 27-year-old male with MDD: A case report and literature review [0.03%]
一份关于一名患有抑郁症的27岁男性迟发布普隆过敏反应的病例报告及文献回顾
Ana Anghel,G Lucy Wilkening
Ana Anghel
Introduction: Bupropion is an antidepressant approved for the treatment of major depressive disorder (MDD), seasonal affective disorder, and smoking cessation. Nausea, headache, tremor, and insomnia are well-known adverse...
Lauren Chaney
Lauren Chaney